RESUMEN
SARS-CoV-2 evolution has continued to generate variants, responsible for new pandemic waves locally and globally. Varying disease presentation and severity has been ascribed to inherent variant characteristics and vaccine immunity. This study analyzed genomic data from 305 whole genome sequences from SARS-CoV-2 patients before and through the third wave in India. Delta variant was reported in patients without comorbidity (97%), while Omicron BA.2 was reported in patients with comorbidity (77%). Tissue adaptation studies brought forth higher propensity of Omicron variants to bronchial tissue than lung, contrary to observation in Delta variants from Delhi. Study of codon usage pattern distinguished the prevalent variants, clustering them separately, Omicron BA.2 isolated in February grouped away from December strains, and all BA.2 after December acquired a new mutation S959P in ORF1b (44.3% of BA.2 in the study) indicating ongoing evolution. Loss of critical spike mutations in Omicron BA.2 and gain of immune evasion mutations including G142D, reported in Delta but absent in BA.1, and S371F instead of S371L in BA.1 could explain very brief period of BA.1 in December 2021, followed by complete replacement by BA.2. Higher propensity of Omicron variants to bronchial tissue, probably ensured increased transmission while Omicron BA.2 became the prevalent variant possibly due to evolutionary trade-off. Virus evolution continues to shape the epidemic and its culmination.Communicated by Ramaswamy H. Sarma.
RESUMEN
BACKGROUND: Globally, amoebic liver abscess, a common extraintestinal complication of intestinal amoebiasis. Diagnosis of hepatic amoebiasis is based on the detection of anti-Entamoeba histolytica immunoglobulin G (IgG) antibody using enzyme-linked immunosorbent assay (ELISA), because of its technique's relatively higher sensitivity and specificity (90%). AIM: The aim of the present study was to determine the seroprevalence of hepatic amoebiasis in a referral tertiary care hospital in North India. MATERIALS AND METHODS: The blood samples were tested specifically for anti-E. histolytica IgG antibody using commercially available ELISA kit (RIDASCREEN®E. histolytica IgG [K1721] kit). RESULTS: A total of 879 patients (n = 879) were evaluated, of which 78.49% (690/879) were positive for anti-E. histolytica IgG antibody. The seroprevalence rates showed a declining trend from 2010 to 2015 with rates falling from 91.4% to 66.7%. He present a study showed the decreasing trend of seroprevalence of hepatic amoebiasis from 2010 to 2015. CONCLUSIONS: This decrease may be attributed to several factors such as increase in awareness, improved hygienic practices, use of safe drinking water, better socioeconomic condition, and perhaps early treatment sought for intestinal amoebiasis.